We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

91 hedge funds and large institutions have $246M invested in Cytokinetics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more call options, than puts

Call options by funds: $3.51M | Put options by funds: $1.35M

62% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 21

3% less capital invested

Capital invested by funds: $254M → $246M (-$8.08M)

4% less funds holding

Funds holding: 95 → 91 (-4)

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
91
Holders Change
-4
Holders Change %
-4.21%
% of All Funds
2.43%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
14
Increased
34
Reduced
21
Closed
18
Calls
$3.51M
Puts
$1.35M
Net Calls
+$2.17M
Net Calls Change
+$1.73M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.3M
2
State Street
State Street
Massachusetts
+$3.65M
3
Millennium Management
Millennium Management
New York
+$3.26M
4
Invesco
Invesco
Georgia
+$900K
5
Two Sigma Investments
Two Sigma Investments
New York
+$822K

Top Sellers

1
EC
EcoR1 Capital
California
-$13.5M
2
ACA
Avoro Capital Advisors
New York
-$4.78M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$3.17M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.1M
5
IHM
Iguana Healthcare Management
New York
-$1.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
26
BlackRock Advisors
Delaware
$1.13M +$11.6K +1,115 +0.9%
Charles Schwab
27
Charles Schwab
California
$1.1M +$659K +63,104 +111%
HVC
28
Healthcare Value Capital
New Jersey
$918K – – –
Invesco
29
Invesco
Georgia
$918K +$900K +86,195 +625%
PAM
30
Panagora Asset Management
Massachusetts
$866K +$183K +17,533 +23%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$823K +$478K +45,800 +104%
CAM
32
ClariVest Asset Management
California
$820K – – –
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$759K – – –
Two Sigma Investments
34
Two Sigma Investments
New York
$723K +$822K +78,710 New
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$656K +$5.22K +500 +0.7%
HCM
36
Highbridge Capital Management
New York
$543K +$617K +59,075 New
Morgan Stanley
37
Morgan Stanley
New York
$493K +$480K +45,995 +602%
TA
38
Teachers Advisors
New York
$471K – – –
Ohio Public Employees Retirement System (OPERS)
39
Ohio Public Employees Retirement System (OPERS)
Ohio
$469K – – –
KeyBank National Association
40
KeyBank National Association
Ohio
$405K – – –
Tudor Investment Corp
41
Tudor Investment Corp
Connecticut
$379K +$259K +24,830 +151%
Citadel Advisors
42
Citadel Advisors
Florida
$377K +$429K +41,046 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$320K -$61.2K -5,860 -14%
CGH
44
Crossmark Global Holdings
Texas
$311K +$224K +21,460 New
CS
45
Credit Suisse
Switzerland
$297K +$98.9K +9,472 +41%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$291K -$76.9K -7,369 -19%
VEA
47
Virtus ETF Advisers
New York
$270K – – –
MLICM
48
Metropolitan Life Insurance Company (MetLife)
New York
$252K – – –
Group One Trading
49
Group One Trading
Illinois
$245K +$142K +13,637 +105%
AllianceBernstein
50
AllianceBernstein
Tennessee
$243K – – –
1
2
3 4 5

CYTK Hedge Fund Activity: Q3 2016 in Review

91 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2016, worth a combined $246M — down 3.2% from $254M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CYTK and 14 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 34 added.

The largest buyer was Fidelity Investments, adding an estimated $18.3M. The largest seller was EcoR1 Capital, cutting an estimated $13.5M.

  • 91 institutional investors held Cytokinetics (CYTK) as of Q3 2016, down from 95 in Q2 2016.
  • Funds reported $246M of Cytokinetics stock for Q3 2016, down 3.2% quarter-over-quarter.
  • 14 funds opened new Cytokinetics positions in Q3 2016 and 18 closed out, a net change of -4 holders.
  • The largest Cytokinetics buyer in Q3 2016 was Fidelity Investments, an estimated $18.3M added.
  • The largest Cytokinetics seller in Q3 2016 was EcoR1 Capital, an estimated $13.5M sold.

Based on aggregated 13F filings for Q3 2016.